Angitia Biopharmaceuticals secured $130 million in Series D financing to advance human trials of new drugs targeting musculoskeletal diseases.
Amount Raised
$130 Million
Round Type
Series D
Los AngelesBiotechnologyTherapeuticsInvestors
Description
Angitia Biopharmaceuticals has raised $130 million in a Series D round to support its development of biologic therapies for musculoskeletal conditions. The funding will help advance several clinical-stage programs, notably its Phase 2 osteoporosis candidate. Angitia aims to address treatment gaps in osteoporosis, particularly among postmenopausal women. The company’s bispecific antibody, AGA2118, targets two proteins to enhance bone mineral density.
Quick answer
Angitia Biopharmaceuticals raised $130 Million in a Series D round, dated February 6, 2026. Investors: Wellington Management, RA Capital Management, Logos Capital, BVF Partners and Ascenta Capital. Angitia Biopharmaceuticals is based in Los Angeles, California, United States.
- How much did Angitia Biopharmaceuticals raise?
- Angitia Biopharmaceuticals raised $130 Million in a Series D round on February 6, 2026.
- Who invested in Angitia Biopharmaceuticals?
- Wellington Management, RA Capital Management, Logos Capital, BVF Partners and Ascenta Capital are named as investors in this round.
- What does Angitia Biopharmaceuticals do?
- Angitia Biopharmaceuticals is a clinical-stage biotechnology company developing novel therapies aimed at improving musculoskeletal health.
- Where is Angitia Biopharmaceuticals based and how big is it?
- Angitia Biopharmaceuticals is based in Los Angeles, California, United States. Fundz records about 51 employees.
- Who are the decision-makers at Angitia Biopharmaceuticals?
- Fundz holds 1 contact at Angitia Biopharmaceuticals, including the Founder and CEO. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Angitia Biopharmaceuticals that raised within 45 days of this round, from Fundz verified event records.
- Diamyd Medical raised $125M (Funding Round) on March 23, 2026.
- Oryon Cell Therapies raised $21M (Series A) on March 23, 2026.
- Amani Therapeutics raised $25M (Series A) on March 23, 2026.
- Tempest Therapeutics raised $2M on March 20, 2026.
- Azitra raised $11M (Post-IPO Equity) on March 19, 2026.
- VST BIO Corporation raised an undisclosed amount (Series A) on March 17, 2026.
Who to call at Angitia Biopharmaceuticals, and when
A new round usually means Angitia Biopharmaceuticals is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Angitia Biopharmaceuticals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Angitia Biopharmaceuticals, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Angitia Biopharmaceuticals. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Angitia Biopharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Angitia Biopharmaceuticals raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.